» Articles » PMID: 38002272

MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Nov 25
PMID 38002272
Authors
Affiliations
Soon will be listed here.
Abstract

In the past decade, significant advances in molecular research have provided a deeper understanding of the intricate regulatory mechanisms involved in carcinogenesis. MicroRNAs, short non-coding RNA sequences, exert substantial influence on gene expression by repressing translation or inducing mRNA degradation. In the context of cancer, miRNA dysregulation is prevalent and closely associated with various stages of carcinogenesis, including initiation, progression, and metastasis. One crucial aspect of the cancer phenotype is the activity of histone-modifying enzymes that govern chromatin accessibility for transcription factors, thus impacting gene expression. Recent studies have revealed that miRNAs play a significant role in modulating these histone-modifying enzymes, leading to significant implications for genes related to proliferation, differentiation, and apoptosis in cancer cells. This article provides an overview of current research on the mechanisms by which miRNAs regulate the activity of histone-modifying enzymes in the context of cancer. Both direct and indirect mechanisms through which miRNAs influence enzyme expression are discussed. Additionally, potential therapeutic implications arising from miRNA manipulation to selectively impact histone-modifying enzyme activity are presented. The insights from this analysis hold significant therapeutic promise, suggesting the utility of miRNAs as tools for the precise regulation of chromatin-related processes and gene expression. A contemporary focus on molecular regulatory mechanisms opens therapeutic pathways that can effectively influence the control of tumor cell growth and dissemination.

Citing Articles

Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.

Baumann A, Buribayev Z, Wolkenhauer O, Salybekov A, Wolfien M Epigenomes. 2025; 9(1).

PMID: 39982247 PMC: 11843950. DOI: 10.3390/epigenomes9010005.


Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.


Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

Jasim S, Ahmed A, Kubaev A, Kyada A, Alshahrani M, Sharma S Med Oncol. 2024; 41(11):265.

PMID: 39400677 DOI: 10.1007/s12032-024-02529-9.


KLF4 is an epigenetically modulated, context-dependent tumor suppressor.

Frazzi R Front Cell Dev Biol. 2024; 12:1392391.

PMID: 39135777 PMC: 11317372. DOI: 10.3389/fcell.2024.1392391.


The Brain-Gut Axis, an Important Player in Alzheimer and Parkinson Disease: A Narrative Review.

Caradonna E, Nemni R, Bifone A, Gandolfo P, Costantino L, Giordano L J Clin Med. 2024; 13(14).

PMID: 39064171 PMC: 11278248. DOI: 10.3390/jcm13144130.


References
1.
Noonan E, Place R, Pookot D, Basak S, Whitson J, Hirata H . miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009; 28(14):1714-24. DOI: 10.1038/onc.2009.19. View

2.
Wang W, Liu Z, Zhang X, Liu J, Gui J, Cui M . miR-211-5p is down-regulated and a prognostic marker in bladder cancer. J Gene Med. 2020; 22(12):e3270. DOI: 10.1002/jgm.3270. View

3.
Wang Y, Toh H, Chow P, Chung A, Meyers D, Cole P . MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012; 26(7):3032-41. PMC: 3382089. DOI: 10.1096/fj.11-201855. View

4.
Roush S, Slack F . The let-7 family of microRNAs. Trends Cell Biol. 2008; 18(10):505-16. DOI: 10.1016/j.tcb.2008.07.007. View

5.
Mirzaei S, Gholami M, Hushmandi K, Hashemi F, Zabolian A, Canadas I . The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022; 15(1):18. PMC: 8892735. DOI: 10.1186/s13045-022-01235-1. View